Investigation of COVID-19 symptoms and potential immunity in the general population

TRACK-COVID: a population-based epidemiological investigation of COVID-19 virus infection

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN55886926

Enrollment

90000

Registered

2020-06-01

Start date

2021-05-17

Completion date

Unknown

Last updated

2020-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 (SARS-CoV-2 infection) symptoms and seroprevalence in the general population Infections and Infestations

Interventions

Participants will be asked to provide monthly online questionnaire information for 12 months. The questionnaire will ask about COVID-19 related symptom experiences within last month, current medicatio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Have previously taken part in the INTERVAL, COMPARE or STRIDES studies 2. Have an email address for study participation 3. Reside in mainland England 4. Have a good understanding of the English language, both written and oral (study materials are not tailored to support non-English language speakers)

Exclusion criteria

Exclusion criteria: 1. Have received three invitations from the INTERVAL/COMPARE/ STRIDES research study team to take part in other studies in the past year 2. Have withdrawn their consent to take part in the INTERVAL/COMPARE/STRIDES study

Design outcomes

Primary

Measure	Time frame
1. Symptoms compatible with COVID-19 measured using online questionnaire information monthly for 12 months 2. Population immunity measured using assay of biomarkers (e.g., IgG antibodies to SARS-CoV-2) on blood samples (obtained at home via finger prick) monthly for 12 months	—

Secondary

Measure	Time frame
1. Asymptomatic or subclinical infections in the population measured using self-reported questionnaire data monthly for 12 months 2. Immunological evidence of previous SARS-CoV-2 infection measured using antibody tests monthly for 12 months 3. Risk factors for subsequent development of any, mild and severe COVID-19 like illnesses (correlates of protection) measured using self-reported monthly questionnaires with concurrent assessment of SARS-Cov-2 specific antibody levels monthly for 12 months 4. Duration of protection from COVID-19 like illness after confirmed infection, measured using SARS-Cov-2 specific antibody levels monthly for 12 months	—

Measure

Time frame

1. Asymptomatic or subclinical infections in the population measured using self-reported questionnaire data monthly for 12 months 2. Immunological evidence of previous SARS-CoV-2 infection measured using antibody tests monthly for 12 months 3. Risk factors for subsequent development of any, mild and severe COVID-19 like illnesses (correlates of protection) measured using self-reported monthly questionnaires with concurrent assessment of SARS-Cov-2 specific antibody levels monthly for 12 months 4. Duration of protection from COVID-19 like illness after confirmed infection, measured using SARS-Cov-2 specific antibody levels monthly for 12 months

—

Countries

United Kingdom

Contacts

Public ContactAmy McMahon

helpdesk@trackcovid.org.uk+44 (0)800 021 7182

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026